Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prednisone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,176 result(s) found for: Prednisone. Displaying page 1 of 59.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-006022-25 Sponsor Protocol Number: WA28119 Start Date*: 2013-05-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS
    Medical condition: Giant cell arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) AT (Completed) DE (Completed) DK (Completed) GB (Completed) PT (Completed) NL (Completed) ES (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004809-31 Sponsor Protocol Number: CAIN457R12301 Start Date*: 2021-09-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placeb...
    Medical condition: giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) BG (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001539-30 Sponsor Protocol Number: C21013 Start Date*: 2012-09-27
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer
    Medical condition: progressive castration-resistant prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed) GR (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001269-10 Sponsor Protocol Number: Doc-Pred Start Date*: 2016-07-14
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: A pharmacokinetic study of Docetaxel and Prednisone in men with metastatic castration-resistant or hormone-sensitive prostate cancer.
    Medical condition: Metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006713-25 Sponsor Protocol Number: ASSENTE Start Date*: 2008-09-23
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: A SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA
    Medical condition: ANEMIE EMOLITICHE AUTOIMMUNI IDIOPATICHE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001618-18 Sponsor Protocol Number: 15782401 Start Date*: 2016-07-08
    Sponsor Name:CHU Toulouse
    Full Title: STAR Comparison of two STrategies of glucocorticoid withdrawal in rheumatoid Arthritis patients in low disease activity or Remission
    Medical condition: glucocorticoid withdrawal in rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002988-18 Sponsor Protocol Number: EFC15068 Start Date*: 2018-11-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) DK (Completed) HU (Completed) FR (Completed) SE (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) PT (Completed) SI (Completed) BE (Prematurely Ended) HR (Completed) GB (GB - no longer in EU/EEA) NO (Completed) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003189-29 Sponsor Protocol Number: ONCO-01-2017 Start Date*: 2018-02-09
    Sponsor Name:L'Institut Mutualiste Montsouris
    Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001215-69 Sponsor Protocol Number: 69HCL17_0020 Start Date*: 2018-09-24
    Sponsor Name:Hospices Civils de Lyon
    Full Title: MAINEPSAN Study A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of ...
    Medical condition: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA, Wegener’s) or microscopic polyangiitis (MPA) , 12 months after initiation of treatment for vasculitis onset or flar...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002419-14 Sponsor Protocol Number: IRST189.04 Start Date*: 2015-09-02
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PRE...
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018661-35 Sponsor Protocol Number: C21004 Start Date*: 2010-10-14
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant...
    Medical condition: Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) HU (Completed) EE (Completed) BE (Completed) SK (Completed) LV (Completed) FI (Completed) NL (Completed) ES (Completed) LT (Completed) CZ (Completed) AT (Completed) GB (Completed) PT (Completed) SE (Completed) IE (Completed) DE (Completed) PL (Completed) IT (Completed) BG (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-004385-16 Sponsor Protocol Number: ME/2005/2073 Start Date*: 2006-01-03
    Sponsor Name:United Bristol Healthcare NHS Trust
    Full Title: CIRCADIAN VARIATIONS IN CYTOKINES AND THE EFFECT OF TIMED RELEASE TABLET PREDNISONE IN RHEUMATOID ARTHRITIS
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004673-16 Sponsor Protocol Number: MA29585 Start Date*: 2016-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Prospective, multicentre, placebo-controlled, double-blind study to compare the efficacy of maintenance treatment with tocilizumab with or without glucocorticoid discontinuation in rheumatoid arth...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001865-41 Sponsor Protocol Number: CC-5013-MM-015 Start Date*: 2007-03-27
    Sponsor Name:Celgene International Sàrl
    Full Title: A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) FR (Completed) DE (Completed) IE (Completed) CZ (Completed) AT (Completed) GB (Completed) DK (Completed) SE (Completed) IT (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-007728-16 Sponsor Protocol Number: P051055 Start Date*: 2009-01-15
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Comparaison de deux stratégies de sevrage de la corticothérapie chez les myasthéniques traités par Prednisone-Azathioprine
    Medical condition: Myasthénie auto-immune généralisée
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028417 Myasthénie auto-immune généralisée PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002125-27 Sponsor Protocol Number: OPZ006 Start Date*: 2013-12-19
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002940-26 Sponsor Protocol Number: 212082PCR3011 Start Date*: 2013-05-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me...
    Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004116-22 Sponsor Protocol Number: MK-3475-921 Start Date*: 2019-04-29
    Sponsor Name:Merck Sharp & Dohme LCC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic ...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002366-12 Sponsor Protocol Number: Protocolversion1.0 Start Date*: 2020-04-08
    Sponsor Name:Johns Hopkins University
    Full Title: ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE)Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10022557 Intermediate uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 05:06:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA